Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Redox tolerance and metabolic reprogramming in solid tumors
Keywan Mortezaee
Cell Biology International (2020) Vol. 45, Iss. 2, pp. 273-286
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Angiogenesis as a hallmark of solid tumors - clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 715-737
Closed Access | Times Cited: 186
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor, Keywan Mortezaee
Clinical Immunology (2021) Vol. 226, pp. 108707-108707
Closed Access | Times Cited: 171
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 112
Advances in dendritic cell vaccination therapy of cancer
Sajad Najafi, Keywan Mortezaee
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114954-114954
Open Access | Times Cited: 47
The current knowledge concerning solid cancer and therapy
Masoud Najafi, Jamal Majidpoor, Heidar Toolee, et al.
Journal of Biochemical and Molecular Toxicology (2021) Vol. 35, Iss. 11
Closed Access | Times Cited: 89
The impact of hypoxia on immune state in cancer
Keywan Mortezaee, Jamal Majidpoor
Life Sciences (2021) Vol. 286, pp. 120057-120057
Closed Access | Times Cited: 70
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
Life Sciences (2021) Vol. 277, pp. 119627-119627
Closed Access | Times Cited: 60
Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products
Holya A. Lafta, Ali Hamid AbdulHussein, Saif A. J. Al-Shalah, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 12, pp. 1104-1122
Closed Access | Times Cited: 39
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114646-114646
Open Access | Times Cited: 26
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Keywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114824-114824
Open Access | Times Cited: 24
Interleukin-2 therapy of cancer-clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2021) Vol. 98, pp. 107836-107836
Closed Access | Times Cited: 53
Organ Tropism in Solid Tumor Metastasis: An Updated Review
Keywan Mortezaee
Future Oncology (2021) Vol. 17, Iss. 15, pp. 1943-1961
Closed Access | Times Cited: 46
Normalization in tumor ecosystem: Opportunities and challenges
Keywan Mortezaee
Cell Biology International (2021) Vol. 45, Iss. 10, pp. 2017-2030
Closed Access | Times Cited: 42
Checkpoint inhibitor/interleukin‐based combination therapy of cancer
Keywan Mortezaee, Jamal Majidpoor
Cancer Medicine (2022) Vol. 11, Iss. 15, pp. 2934-2943
Open Access | Times Cited: 37
Modulation of the immune system by melatonin; implications for cancer therapy
Masoud Moslehi, Reza Moazamiyanfar, Mohammad Sedigh Dakkali, et al.
International Immunopharmacology (2022) Vol. 108, pp. 108890-108890
Closed Access | Times Cited: 35
(Im)maturity in Tumor Ecosystem
Keywan Mortezaee, Jamal Majidpoor
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 33
Bladder Cancer‐Derived Small Extracellular Vesicles Promote Tumor Angiogenesis by Inducing HBP‐Related Metabolic Reprogramming and SerRS O‐GlcNAcylation in Endothelial Cells
Xinyuan Li, Xiang Peng, Chunlin Zhang, et al.
Advanced Science (2022) Vol. 9, Iss. 30
Open Access | Times Cited: 32
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
Arian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2023) Vol. 118, pp. 110032-110032
Closed Access | Times Cited: 16
Key promoters of tumor hallmarks
Keywan Mortezaee, Jamal Majidpoor
International Journal of Clinical Oncology (2021) Vol. 27, Iss. 1, pp. 45-58
Closed Access | Times Cited: 36
The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer
Fabrizio Fontana, Patrízia Limonta
Free Radical Biology and Medicine (2021) Vol. 176, pp. 203-221
Closed Access | Times Cited: 33
Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Shahram Taeb, Milad Ashrafizadeh, Ali Zarrabi, et al.
Current Cancer Drug Targets (2021) Vol. 22, Iss. 1, pp. 18-30
Closed Access | Times Cited: 33
Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated
Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad
Medical Oncology (2022) Vol. 39, Iss. 12
Closed Access | Times Cited: 27
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi
Life Sciences (2022) Vol. 310, pp. 121083-121083
Closed Access | Times Cited: 26
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated
Keywan Mortezaee, Jamal Majidpoor
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 3, pp. 311-321
Open Access | Times Cited: 13
Pathogenic mitochondrial dysfunction and metabolic abnormalities
Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, et al.
Biochemical Pharmacology (2021) Vol. 193, pp. 114809-114809
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top